Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents
Identifieur interne : 001D74 ( Main/Exploration ); précédent : 001D73; suivant : 001D75Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents
Auteurs : Jason E. Brouillard ; Colleen M. Terriff ; Andreea Tofan ; Mark W. Garrison [Canada]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2006-01.
Abstract
Bacillus anthracis (anthrax), Yersinia pestis (plague), Francisella tularensis (tularemia), Coxiella burnetti (Q fever), and Brucella sp (brucellosis) are all potential bioterrorism agents. Their known virulence, potential lethality, and ability to develop resistance to known antibiotic treatments make these pathogens particularly dangerous. We reviewed the scientific literature by searching MEDLINE databases and published abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America from 1989–2005 for studies of each of these biologic agents with the specific aim of examining whether doxycycline or a fluoroquinolone should be stockpiled for mass‐scale postexposure prophylaxis. An evidence‐based approach was used to determine whether doxycycline or fluoroquinolones were efficacious (both in vitro and in vivo) against these biologic agents and to examine these drugs' respective susceptibility patterns and differences in cost, based on available data. Little published data are available on these pathogens, and much of the data are from studies that used older strains obtained from patient or animal sources in outbreaks decades ago. Doxycycline appears to show comparable minimum inhibitory concentrations to those of the fluoroquinolone class in most clinical and in vitro studies, perhaps with the exception of inhalation plague. Studies also suggest that development of antibiotic resistance is less likely to occur with doxycycline. Doxycycline is several‐fold less expensive than most fluoroquinolones and appears to have similar efficacy in most scenarios based on clinical case studies and established Clinical and Laboratory Standards Institute (formerly known as the National Committee for Clinical Laboratory Standards) breakpoints for staphylococci. Therefore, doxycycline should be considered as a first‐line antibiotic in the management of bioterrorism agents.
Url:
DOI: 10.1592/phco.2006.26.1.3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A83
- to stream Istex, to step Curation: 001A83
- to stream Istex, to step Checkpoint: 000C42
- to stream Main, to step Merge: 001D86
- to stream Main, to step Curation: 001D74
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents</title><author><name sortKey="Brouillard, Jason E" sort="Brouillard, Jason E" uniqKey="Brouillard J" first="Jason E." last="Brouillard">Jason E. Brouillard</name></author><author><name sortKey="Terriff, Colleen M" sort="Terriff, Colleen M" uniqKey="Terriff C" first="Colleen M." last="Terriff">Colleen M. Terriff</name></author><author><name sortKey="Tofan, Andreea" sort="Tofan, Andreea" uniqKey="Tofan A" first="Andreea" last="Tofan">Andreea Tofan</name></author><author><name sortKey="Garrison, Mark W" sort="Garrison, Mark W" uniqKey="Garrison M" first="Mark W." last="Garrison">Mark W. Garrison</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:31C8E536FB1749B88AAD72496A323553BAF44F23</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1592/phco.2006.26.1.3</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-PTRP6FRM-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001A83</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A83</idno><idno type="wicri:Area/Istex/Curation">001A83</idno><idno type="wicri:Area/Istex/Checkpoint">000C42</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C42</idno><idno type="wicri:doubleKey">0277-0008:2006:Brouillard J:antibiotic:selection:and</idno><idno type="wicri:Area/Main/Merge">001D86</idno><idno type="wicri:Area/Main/Curation">001D74</idno><idno type="wicri:Area/Main/Exploration">001D74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents</title><author><name sortKey="Brouillard, Jason E" sort="Brouillard, Jason E" uniqKey="Brouillard J" first="Jason E." last="Brouillard">Jason E. Brouillard</name><affiliation><wicri:noCountry code="subField">University</wicri:noCountry></affiliation></author><author><name sortKey="Terriff, Colleen M" sort="Terriff, Colleen M" uniqKey="Terriff C" first="Colleen M." last="Terriff">Colleen M. Terriff</name><affiliation></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: terrifc@empirehealth.org</wicri:noCountry></affiliation></author><author><name sortKey="Tofan, Andreea" sort="Tofan, Andreea" uniqKey="Tofan A" first="Andreea" last="Tofan">Andreea Tofan</name><affiliation><wicri:noCountry code="subField">Center</wicri:noCountry></affiliation></author><author><name sortKey="Garrison, Mark W" sort="Garrison, Mark W" uniqKey="Garrison M" first="Mark W." last="Garrison">Mark W. Garrison</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Spokane, Washington; and the Pharmacy Department, Royal Columbian Hospital, New Westminster, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><title level="j" type="alt">PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="3">3</biblScope><biblScope unit="page" to="14">14</biblScope><biblScope unit="page-count">12</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2006-01">2006-01</date></imprint><idno type="ISSN">0277-0008</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bacillus anthracis (anthrax), Yersinia pestis (plague), Francisella tularensis (tularemia), Coxiella burnetti (Q fever), and Brucella sp (brucellosis) are all potential bioterrorism agents. Their known virulence, potential lethality, and ability to develop resistance to known antibiotic treatments make these pathogens particularly dangerous. We reviewed the scientific literature by searching MEDLINE databases and published abstracts from the Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America from 1989–2005 for studies of each of these biologic agents with the specific aim of examining whether doxycycline or a fluoroquinolone should be stockpiled for mass‐scale postexposure prophylaxis. An evidence‐based approach was used to determine whether doxycycline or fluoroquinolones were efficacious (both in vitro and in vivo) against these biologic agents and to examine these drugs' respective susceptibility patterns and differences in cost, based on available data. Little published data are available on these pathogens, and much of the data are from studies that used older strains obtained from patient or animal sources in outbreaks decades ago. Doxycycline appears to show comparable minimum inhibitory concentrations to those of the fluoroquinolone class in most clinical and in vitro studies, perhaps with the exception of inhalation plague. Studies also suggest that development of antibiotic resistance is less likely to occur with doxycycline. Doxycycline is several‐fold less expensive than most fluoroquinolones and appears to have similar efficacy in most scenarios based on clinical case studies and established Clinical and Laboratory Standards Institute (formerly known as the National Committee for Clinical Laboratory Standards) breakpoints for staphylococci. Therefore, doxycycline should be considered as a first‐line antibiotic in the management of bioterrorism agents.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Brouillard, Jason E" sort="Brouillard, Jason E" uniqKey="Brouillard J" first="Jason E." last="Brouillard">Jason E. Brouillard</name><name sortKey="Terriff, Colleen M" sort="Terriff, Colleen M" uniqKey="Terriff C" first="Colleen M." last="Terriff">Colleen M. Terriff</name><name sortKey="Tofan, Andreea" sort="Tofan, Andreea" uniqKey="Tofan A" first="Andreea" last="Tofan">Andreea Tofan</name></noCountry><country name="Canada"><noRegion><name sortKey="Garrison, Mark W" sort="Garrison, Mark W" uniqKey="Garrison M" first="Mark W." last="Garrison">Mark W. Garrison</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:31C8E536FB1749B88AAD72496A323553BAF44F23
|texte= Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents
}}
| This area was generated with Dilib version V0.6.33. |  |